NCT04513925已完成3 期
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 829
- 试验地点
- 365
- 主要终点
- Independent Review Facility (IRF)-assessed Progression Free Survival (PFS) in the PD-L1-positive Analysis Set (PPAS)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Histologically or cytologically documented NSCLC with locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology
- •Whole-body Positron Emission Tomography-Computed Tomography (PET-CT) scan, performed prior and within 42 days of the first dose of concurrent chemoradiotherapy (cCRT)
- •At least two prior cycles of platinum-based chemotherapy administered concurrently with radiotherapy (RT), which must be completed within 1 to 42 days prior to randomization in the study (one cycle of cCRT is defined as 21 or 28 days)
- •The radiotherapy (RT) component in the cCRT must have been at a total dose of radiation of 60 (±10 percent [%]) gray (Gy) (54 Gy to 66 Gy) administered by intensity modulated RT (preferred) or 3D-conforming technique
- •No progression during or following concurrent platinum-based CRT
- •A known PD-L1 result
- •Life expectancy >/= 12 weeks
- •Adequate hematologic and end-organ function
- •Female participants must be willing to avoid pregnancy for 90 days after the final dose of tiragolumab and 5 months after the final dose of atezolizumab, or for 3 months after the final dose of durvalumab
- •Male participants must remain abstinent or use a condom during the treatment period and for 90 days after the final dose of tiragolumab
- •Male participants must not donate sperm during the treatment period and for 90 days after the final dose of tiragolumab
排除标准
- •Any history of prior NSCLC and/or any history of prior treatment for NSCLC (participants must be newly diagnosed with unresectable Stage III disease)
- •NSCLC known to have a mutation in the epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) fusion oncogene
- •Any evidence of Stage IV disease
- •Treatment with sequential CRT for locally advanced NSCLC
- •Participants with locally advanced NSCLC who have progressed during or after the definitive cCRT prior to randomization
- •Any Grade >2 unresolved toxicity from previous CRT
- •Grade >= 2 pneumonitis from prior CRT
- •Active or history of autoimmune disease or immune deficiency
- •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis or evidence of active pneumonitis
- •History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with a negligible risk of metastasis or death
- •Prior allogeneic stem cell or solid organ transplantation
- •Active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening
- •Treatment with investigational therapy within 28 days prior to initiation of study treatment
- •Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-T-cell immunoreceptor with Ig and ITIM domains (anti-TIGIT), anti-PD-1 and anti-PD-L1
- •Any prior Grade >/= 3 immune-mediated adverse event or any unresolved Grade > 1 immune-mediated adverse event while receiving any previous immunotherapy agent other than immune checkpoint blockade agents
- •Treatment with systemic immunosuppressive medication
- •Women who are pregnant, or breastfeeding
研究组 & 干预措施
Atezolizumab + Tiragolumab
Experimental
Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
干预措施: Atezolizumab (Drug)
Atezolizumab + Tiragolumab
Experimental
Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
干预措施: Tiragolumab (Drug)
Durvalumab
Active Comparator
Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.
干预措施: Durvalumab (Drug)
结局指标
主要结局
Independent Review Facility (IRF)-assessed Progression Free Survival (PFS) in the PD-L1-positive Analysis Set (PPAS)
时间窗: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 114 months)
IRF-assessed PFS in the Full Analysis Set (FAS)
时间窗: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 114 months)
次要结局
- Investigator-assessed PFS in the PPAS(Time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first first (up to approximately 114 months))
- IRF-assessed Confirmed Objective Response Rate (ORR) in the PPAS(From randomization up to approximately 114 months)
- IRF-assessed Duration of Response (DOR) in the PPAS(From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months))
- Overall Survival (OS) in the PPAS(From randomization to death from any cause (up to approximately 114 months))
- Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score in the PPAS(Up to approximately 114 months)
- TTCD Assessed Using EORTC QLQ-C30 Score in the FAS(Up to approximately 114 months)
- OS Rates at 12 Months, 24 Months, 36 Months and 48 Months in the FAS(12, 24, 36 and 48 months)
- Investigator-assessed Confirmed ORR in the PPAS(From randomization up to approximately 114 months)
- OS in the FAS(From randomization to death from any cause (up to approximately 114 months))
- Investigator-assessed DOR in the PPAS(From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months))
- Investigator-assessed PFS in the FAS(Time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first first (up to approximately 114 months))
- IRF-assessed DOR in the FAS(From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months))
- IRF-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the PPAS(12, 18 and 24 months)
- IRF-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the FAS(12, 18 and 24 months)
- OS Rates at 12 Months, 24 Months, 36 Months and 48 Months in the PPAS(12, 24, 36 and 48 months)
- Investigator-assessed Time to Death or Distant Metastasis (TTDM) in the PPAS(From randomization until the first date of distant metastasis or death in the absence of distant metastasis (up to approximately 114 months))
- Percentage of Participants With Adverse Events(Up to approximately 114 months)
- IRF-assessed Confirmed ORR in the FAS(From randomization up to approximately 114 months)
- Investigator-assessed Confirmed ORR in the FAS(From randomization up to approximately 114 months)
- Investigator-assessed DOR in the FAS(From first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 114 months))
- Investigator-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the PPAS(12, 18 and 24 months)
- Investigator-assessed PFS Rates at 12 Months, 18 Months and 24 Months in the FAS(12, 18 and 24 months)
- Investigator-assessed TTDM in the FAS(From randomization until the first date of distant metastasis or death in the absence of distant metastasis (up to approximately 114 months))
研究者
研究点 (365)
Loading locations...
相似试验
已完成
3 期
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCarcinoma, HepatocellularNCT03434379Hoffmann-La Roche558
已完成
3 期
A phase III study of atezolizumab in patients with hepatocellular carcinomaHepatocellular carcinomaJPRN-jRCT2080223820CHUGAI PHARMACEUTICAL CO., LTD.501
已完成
3 期
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung CancerNCT02409342Hoffmann-La Roche572
已完成
1 期
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid TumorsSolid TumorNCT02715531Hoffmann-La Roche243
已完成
3 期
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT02366143Hoffmann-La Roche1,202